Introduction
A multidisciplinary approach, combining advances in systemic chemotherapy, targeted agents and aided by better surgical and imaging techniques has significantly enhanced the outcome for patients with metastatic colorectal cancer (mCRC) over the last two decades (Fig. 1) . 1 Advancements in the management of unresectable mCRC have been characterised by small incremental improvements in overall survival which now extends beyond 2 years with the addition of biological agents to standard fluoropyrimidine-based chemotherapy regimens. Today, a whole host of newly identified targeted therapeutic agents inhibiting one or more key pathways are being evaluated in phase III clinical trials (including aflibercept and regorafenib) 2,3 as potential new treatments for mCRC. Our understanding of the benefits of targeted agents has been aided by large well-designed multicentre studies in patients with proven chemorefractory mCRC. While cetuximab initially showed only modest benefits 4 a subsequent study of patients with wild-type K-ras tumours revealed that cetuximab plus best supportive care (BSC) was associated with a doubling overall survival (median, 9.5 vs. 4.8 months for BSC alone; HR for death, 0.55; P < 0.001) in chemorefractory disease. 5 In the same way, the recent evaluation of regorafenib plus BSC showed only a modest improvement in overall survival (median, 6.4 vs. 5.0 months for placebo plus BSC; HR, 0.77 [95% CI: 0.63-0.94; 1-sided P = 0.0051]) in patients with mCRC who progressed after standard therapies, 3 but there is early evidence to suggest that some patients do benefit more than others. 3 Like locoregional treatments, the challenge with targeted agents is to select the cohorts of patients who will benefit most. For targeted agents such as regorafenib, the decision to treat is likely to be based on the identification of a combination of molecular biomarkers (angiogenic signatures) for regorafenib activity.
Locoregional treatment with SIRT
The published evidence suggests that locoregional treatments may play a complementary role to systemic treatment by improving the local control of metastases in the liver. Comparisons between these two treatment modalities cannot be made because the locoregional treatments are used to manage liver-limited or liverpredominant disease while clinical trials of systemic agents include a much broader group of patients including those with disease that has progressed beyond the liver to the lungs and peritoneum. Early evidence for selective internal radiation therapy (SIRT) in mCRC was largely based on small case series. In review of the evidence in 2009, the Cochrane group concluded that there was a need for well-designed, adequately powered phase III trials to assess the effect of SIRT combined with modern chemotherapy regimens. 6 Further studies with SIRT were also needed in chemorefractory disease, with a particular focus on the impact on quality of life. 6 Since this review, four comparative or prospective studies have been published on SIRT in chemorefractory patients (Table 1) . 7−10 One such study at the University Hospitals Leuven in collaboration with other Belgian sites evaluated 44 patients with liver-limited mCRC for whom all other evidence-based treatments had failed. Table 2) . More rarely, radiation-associated gastrointestinal ulcers can occur and these are more difficult to treat. 11 Patients should be carefully monitored with a low threshold of suspicion for evidence of gastrointestinal ulcer to ensure early and effective treatment, especially if subsequent treatment with antiangiogenics such as bevacizumab is being considered. In summary, SIRT is likely to play an important complementary role to systemic therapies for the control of colorectal liver metastases. Ongoing randomised controlled clinical trials with conventional chemotherapies with or without SIRT (in the first-line setting and in chemorefractory disease) will further define the role of this treatment modality in the management of liverdominant mCRC.
